Genes Expression (controls)a Expression (AUD cases)a Effect sizeb Pnominalc Ppermutationd
FBXO21 9.47 9.59 0.12 0.001 0.002
ITPR2e 6.72 6.82 0.12 0.002 0.002
FAM65B 7.21 7.37 0.15 0.005 0.004
ZFYVE21 10.06 10.26 0.23 0.006 0.006
BBS2 9.17 9.31 0.18 0.005 0.007
GPR177 7.78 7.99 0.23 0.007 0.008
JARID2e 8.27 8.41 0.17 0.011 0.010
RAB34 7.05 7.34 0.29 0.012 0.011
C10orf54e 6.89 7.25 0.31 0.012 0.012
SPON1 8.02 8.43 0.43 0.034 0.022
ATP1A2 9.85 10.17 0.44 0.027 0.024
ATP1B2 9.41 9.83 0.44 0.056 0.029
WIF1 7.18 7.44 0.39 0.037 0.032
AFF4 7.66 7.80 0.17 0.022 0.033
BAG3e 7.74 8.25 0.45 0.035 0.033
TUBB2Be 12.31 12.66 0.32 0.029 0.033
SDC4 8.01 8.53 0.49 0.040 0.034
CPT2 7.43 7.59 0.15 0.029 0.035
SLC39A12 7.25 7.54 0.35 0.060 0.038
PCDHB5 6.65 6.69 0.05 0.073 0.040
SLC1A2 10.29 10.74 0.54 0.040 0.041
GJA1 8.78 9.23 0.54 0.054 0.047
TMEM192 6.71 6.75 0.04 0.050 0.048
aMean gene expression levels in controls (or AUD cases) measured by Illumina's HT-12 v4 Gene Expression BeadChip.
bEffect size (or regression coefficients) obtained by multiple linear regression analysis with adjustment for sex, age, and PMI.
cObserved P values obtained by multiple linear regression analysis with adjustment for sex, age, and PMI.
dPermutation P values obtained by R package lmPerm analysis.
eGenes with expression levels negatively correlated with that of miR-130a.
Table 1: 23 differentially expressed genes predicted to be targets of miR-130a.